Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol

(2021) Helen S. Marshall et al.   Human Vaccines & Immunotherapeutics

VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea

(2021) Laura M. Reyes Díaz et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy

(2021) Cecilia Fazio et al.   Human Vaccines & Immunotherapeutics

COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough

(2021) Rita Rubin   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination

(2021) Federico Martinón-Torres et al.   JOURNAL OF INFECTION

The Neisseria gonorrhoeae Vaccine Candidate NHBA Elicits Antibodies That Are Bactericidal, Opsonophagocytic and That Reduce Gonococcal Adherence to Epithelial Cells

(2020) Evgeny A. Semchenko et al.   Vaccines

Synergic complement‐mediated bactericidal activity of monoclonal antibodies with distinct specificity

(2020) Eriberto Noel Natali et al.   FASEB JOURNAL

Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence

(2020) Ray Borrow et al.   JOURNAL OF INFECTION

Strain coverage of Bexsero vaccine assessed by whole-genome sequencing over a cohort of invasive meningococci of serogroups B and W isolated in Switzerland

(2020) Stefano Leo et al.   VACCINE

First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England

(2020) Shamez N Ladhani et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool that Exploits Genomic Data in Public Health and Clinical Microbiology Applications

(2020) Charlene M.C. Rodrigues et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents

(2020) Alessia Biolchi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

(2020) Fernanda M. P. Rodrigues et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae

(2020) Isabelle Leduc et al.   PLoS Pathogens

Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016

(2019) Jane Rowley et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology

(2019) Vega Masignani et al.   Frontiers in Immunology

Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine

(2019) Henju Marjuki et al.   mBio

Gonorrhoea

(2019) Magnus Unemo et al.   Nature Reviews Disease Primers

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes

(2018) M. Giuliani et al.   Scientific Reports

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

(2018) A. W. Dretler et al.   Human Vaccines & Immunotherapeutics

The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae

(2018) Evgeny A Semchenko et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal B vaccine (4CMenB): the journey from research to real world experience

(2018) Rino Rappuoli et al.   Expert Review of Vaccines

Frequent capsule switching in ‘ultra-virulent’ meningococci – Are we ready for a serogroup B ST-11 complex outbreak?

(2017) Jay Lucidarme et al.   JOURNAL OF INFECTION

Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study

(2017) Helen Petousis-Harris et al.   LANCET

Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model

(2017) Y Liu et al.   Mucosal Immunology

Novel approaches to Neisseria meningitidis vaccine design

(2017) Myron Christodoulides et al.   Pathogens and Disease

Possible Impact of Wide-scale Vaccination Against Serogroup B Neisseria Meningitidis on Gonorrhea Incidence Rates in One Region of Quebec, Canada

(2017) Jean Longtin et al.   Open Forum Infectious Diseases

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection

(2016) Ray Borrow et al.   Expert Review of Vaccines

Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined

(2016) Massimiliano Biagini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intractable problems require novel solutions: it's time to get serious about developing a gonorrhoea vaccine

(2016) Evgeny A Semchenko et al.   SEXUALLY TRANSMITTED INFECTIONS

Meningococcal serogroup B vaccines: Estimating breadth of coverage

(2016) Robert G. K. Donald et al.   Human Vaccines & Immunotherapeutics

Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets

(2015) Dennis K.S. Law et al.   BMC MICROBIOLOGY

Neisseria meningitidis: pathogenesis and immunity

(2015) Mariagrazia Pizza et al.   CURRENT OPINION IN MICROBIOLOGY

Mortality From Sexually Transmitted Diseases in Reproductive-Aged Women: United States, 1999–2010

(2014) Kara A. McElligott   AMERICAN JOURNAL OF PUBLIC HEALTH

Neisseria meningitidis; clones, carriage, and disease

(2014) R.C. Read   CLINICAL MICROBIOLOGY AND INFECTION

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain

(2014) Emilio Pérez-Trallero et al.   PLoS One

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future

(2013) Johan Holst et al.   Human Vaccines & Immunotherapeutics

Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae

(2012) Ronza Hadad et al.   APMIS

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens

(2012) Davide Serruto et al.   VACCINE

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

(2012) Eva Hong et al.   VACCINE

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

(2011) Xin Wang et al.   VACCINE

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen

(2011) David M. Vu et al.   VACCINE

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Chlamydia trachomatis infection: host immune responses and potential vaccines

(2008) L Hafner et al.   Mucosal Immunology